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ABSTRACT: Photoswitchable neurotransmitters of ionotropic kainate 
receptors were synthesized by tethering a glutamate moiety to 
disubstituted C2-bridged azobenzenes, which were prepared through a 
novel methodology that allows access to diazocines with higher yields 
and versatility. Because of the singular properties of these 
photochromes, photoisomerizable compounds were obtained with 
larger thermal stability for their inert cis isomer than for their 
biologically activity trans state. This enabled selective neuronal firing 
upon irradiation without background activity in the dark. 
 
By enabling remote manipulation of neuronal signaling with 
light, optogenetics1 and photopharmacology2 have revolution-
ized neuroscience and neurobiology. Neural receptors re-
sponding to glutamate (GluRs), the primary excitatory neuro-
transmitter, are one of the major targets in these fields, since 
they regulate several key processes in the nervous system and 
are related to numerous diseases.3 As such, a plethora of pho-
topharmacological tools have been developed for light-gating 
GluRs,4 among which photochromic ligands (PCLs)5-12 are 
often preferred because they combine (a) the advantages of 
small-molecule, freely diffusing drugs with (b) the capacity 
for reversibly photoswitching their activity without by-product 
generation nor modification of native receptors.2,4 
The major strategy employed to derive PCLs relies on intro-
ducing an azoaromatic photoswitch into the structure of well-
known, biologically-active ligands.2,4 Upon trans-cis photo-
isomerization,13 a geometrical change is induced in these com-
pounds that alters their interaction with the receptor. Typical-
ly, the more extended configuration of the trans isomer favors 
such interaction, while affinity is reduced for the folded cis 
state due to steric effects (i.e. trans-active PCLs).2,4 Because of 
the inherent photochemical properties of azo-aromatic com-
pounds,13 this imposes a severe limitation to most PCLs de-
veloped to date for GluRs5-11 (and other receptors2): they are 
active in the dark, where they lie in the more stable trans state. 
Consequently, these compounds elicit strong tonic responses 
in the absence of illumination (e.g. when acting as receptor 
agonists), which drastically hampers their use. This is the case 
of GluAzo (Figure 1a), which is a trans-active, trans-stable 
partial agonist of ionotropic kainate receptors GluK1 and 
GluK2,5,14,15 two of the principal GluRs mediating excitatory 
neurotransmission in the central nervous system.3 
To overcome this obstacle while preserving the main design 
principles behind azo-based PCLs, bridged azobenzenes 
(brAzo) such as diazocines (C2 bridge, Figure 1b) could be 
used as photochromes, since they (a) should also favor trans-
active behavior by switching between extended trans and bent 
cis configurations, but (b) exhibit cis thermal stability.16-23 This 
combination of properties should therefore allow direct 
administration of the inert cis form of the PCL, which could 
then be selectively photoactivated. In addition, diazocines 
isomerize with visible light,16-23 which is a further advantage 
with respect to common UV-responding azoaromatic 
compounds.13 However, the limited synthetic accessibility and 
versatility of these photochromes has so far limited their 
application to the photocontrol of biological systems.22,23b 
Actually, their use in photopharmacology to modulate the 
activity of N-methyl-D-aspartate (NMDA) receptors and 
potassium ion channels has only been reported very recently,24 
for which a low-yield 4-mono-substituted diazocine previously 





Figure 1. (a) Structure of GluAzo.5 (b) Strategy proposed to 
prepare trans-active, cis-stable PCLs based on C2-bridged azo-
benzenes for the light-control of neuronal membrane receptors 
GluK1 and GluK2. (b) Photoisomerization of Glu_brAzo1-2. 
In this work we aim to apply this strategy to photocontrol 
GluK1 and GluK2, while broadening its scope by developing 
diazocine-based PCLs with larger yields and multiple func-
tionalization sites to favor chemical versatility. To reach this 
goal our attention focused on 3,3’-disubstituted diazo-
cines,17,18,21 because very inefficient syntheses have been re-
ported to date for 4,4’-disubstituted analogues (< 1% yield22). 
Based on these photochromes and the structure of GluAzo,5 
we designed Glu_brAzo2 as the first trans-active, cis-stable 
agonist of GluK1 and GluK2 by tethering a diazocine unit to a 
biologically active glutamate moiety through a vinyl linker 
(Figure 1c). In addition, we took advantage of the disubstitu-
tion pattern of the photochrome to introduce a lateral ionic, 
bulky group for (a) enhancing solubility in aqueous media, and 
(b) further hindering the interaction of the cis isomer with the 
receptor by increasing the steric congestion around the gluta-
mate moiety. The latter should boost the difference in activity 
between the two states of the PCL, a required feature given the 
moderate photoconversions of most functionalized diazo-
cines.17,18,20-23 To evaluate this effect, Glu_brAzo1 lacking the 
additional bulky substituent was also synthesized (Figure 1c). 
 
To validate our design principles, we conducted molecular 
docking simulations for the two isomers of Glu_brAzo1-2 on 
kainate receptors. Our attention particularly focused on 
GluK2, since (a) it presents a narrower binding cavity that 
imposes larger steric constraints to ligands,25 and (b) the crys-
tallographic structure of its ligand-binding domain after com-
plexation with trans-GluAzo is available.15 Dockings were 
computed on this structure keeping the protein rigid, while the 
initial geometries of the PCLs were optimized at the 
B3LYP/6-31G(d) level. In all the cases, the best docking solu-
tions placed the glutamate moiety of the ligands in a very 
similar position as with trans-GluAzo,26 thus suggesting anal-
ogous interaction with the receptor via hydrogen bonds. How-
ever, clear differences were observed for the binding arrange-
ment of each ligand (Figure 2 and S1), which led to different 
complexation energies (in Chemscore units27): 41.2, 37.0, 48.0, 
37.3 for trans-Glu_brAzo1, cis-Glu_brAzo1, trans-
Glu_brAzo2 and cis-Glu_brAzo2 respectively. Importantly, 
these figures indicate larger affinity of the trans isomers of 
Glu_brAzo1-2 to GluK2, thus preserving the targeted trans-
active behavior of GluAzo. By contrast, they do not support 
our hypothesis that the introduction of an ionic, bulky group in 
Glu_brAzo2 should decrease the binding efficiency of the cis 
isomer with respect to less hindered Glu_brAzo1. It must be 
noted, however, that this is compensated by the higher com-
plexation energy calculated for trans-Glu_brAzo2 relative to 
trans-Glu_brAzo1, which arises from the additional attractive 
hydrogen bonding and lipophilic interactions formed between 
its bulky group and the receptor. Therefore, an enhanced con-
trast in biological activity is indeed to be expected between the 
two states of Glu_brAzo2, as originally designed. 
Based on our experience in the synthesis of C2-bridged azo-
benzenes16-21 and light-responsive glutamate ligands,28-30 we 
devised a linear sequence to prepare Glu_brAzo1-2 by Heck 
coupling reaction between their constituting units: a 3,3’-
disubstituted diazocine and previously reported, protected 
glutamate derivative 129 (Scheme 1). The preparation of the 
photochromic unit started from commercially available 4-
bromo-2-nitrotoluene, 3, which was subjected to deprotonation 
with potassium tert-butoxide and further oxidation with bro-
mine to afford dinitro derivative 4. When attempting common 
reductive ring-closing conditions on this intermediate that had 
been previously reported for the synthesis of diazocines (e.g. 
Zn, Ba(OH)2),16-21 formation of the desired bridged azoben-
zene was only observed with very low yields (< 14%). This 
prompted us to develop a new methodology for the azocy-
clization process, for which we explored Mills coupling reac-
tion. With this aim, we first reduced the nitro groups of 4 
using sodium sulphide,3 1 which delivered diamine 5 in 90% 
yield. Then, oxidative coupling of 5 was undertaken in the 
presence of Oxone®3 2 in glacial acetic acid3 3  at room temper-
ature for 1 h, which nicely furnished dibromosubstituted di-
azocine 6 in good yield (40%). According to this result, Ox-
one®-mediated oxidation of one of the aniline moieties to 
provide the corresponding nitrosoarene followed by condensa-
tion with the other, unaltered aniline emerges as a novel one-
pot synthesis of diazocines with reproducible yields. 
Azobenzene 6 was next monocyanated under standard 
Rosenmund-von Braun conditions3 4  to obtain common 
asymmetric diazocine 7 in 78% yield  (based on recovered 6).  
This 
 
Figure 2. Best docking solutions for trans-Glu_brAzo2 (orange) 
and cis-Glu_brAzo2 (green) in GluK2. The protein residues 
interacting with the glutamate group of both ligands are also 
indicated. Oxygen, nitrogen and hydrogen atoms are depicted in 
red, blue and white, respectively. 
 
Scheme 1. Synthesis of Glu_brAzo1 and Glu_brAzo2 
 
compound was directly coupled to glutamate 1 under Palladi-
um catalysis, for which proper selection of the base and the 
solvent was found to be fundamental. After several tests, the 
reaction was performed with K3PO4 and N,N-
dimethylacetamide3 5 at 140 °C under argon in the presence of 
0.1 mol% Pd(OAc)2, which delivered 8 in 61% yield. Finally, 
acid removal of the protecting groups gave the target com-
pound Glu_brAzo1 as its monotrifluoroacetate salt in good 
yield. For Glu_brAzo2, intermediate 7 was hydrolyzed in 
basic medium to give the corresponding acid, which was then 
tethered to previously prepared amine 2 using carbodiimide 
coupling reagent EDCl·HCl along with HOBt to afford 9 in 
74% yield for the two steps. Heck reaction of this compound 
with 1 under the aforementioned conditions and subsequent 
removal of the protecting groups finally delivered the target 
PCL. It must be noted that, despite its larger structural com-
plexity, Glu_brAzo2 was obtained with an overall yield that is 
ca. 2- to 10-fold larger than those recently reported for diazo-
cine-based PCLs,24 thus paving the way for the general appli-
cation of this strategy in photopharmacology. 
By comparison with previous data reported for diazocines,16-21 
NMR and UV-vis absorption analysis confirmed obtainment 
of the cis isomer of Glu_brAzo1-2 due to their larger stability. 
In addition, upon irradiation of their n-π* absorption band with 
violet light (abs,max  395 nm, exc = 405 nm), spectral changes 
were observed indicative of cis-trans isomerization (Figures 
3a and S2-S4). This is the case of the new red-shifted absorp-
tion band found at abs,max  480 nm, which is distinctive of the 
trans isomer of diazocines16-18,20-23 and allowed reverting the 
isomerization process by green light illumination (exc = 532 
nm, Figure 3a and S2-S3 and S5). Further characterization of 
Glu_brAzo1-2 revealed that they undergo cis-trans photo-
isomerization with moderate quantum yields (cis-trans  0.1) 
and efficiencies in aqueous media (Table S1), which resulted 
in photostationary state mixtures (PSScis-trans) containing 47% 
and 60% of their trans isomer, respectively. By contrast, 
trans-cis photoconversion proceeded quantitatively with high 
quantum yields (trans-cis  0.9), thus ensuring fast light-induced 
recovery of cis-Glu_brAzo1-2 (Table S1) and repetitive photo-
switching without degradation (Figure S6). Back-isomerization 
of the trans state of these compounds was also found to occur 
in the dark, though at a very much longer time scale (t1/2  4 h 
at 298 K in aqueous media, Figure S7 and Table S1). 
To assess the capacity of Glu_brAzo1-2 to light-gate GluRs, 
whole-cell voltage clamp recordings were conducted on 
HEK293 cells expressing GluK1 or GluK2, whose activation 
causes channel opening and ion flux across the membrane 
(Figure 1b).3,5 After perfusion of Glu_brAzo1-2, clear chang-
es in the currents evoked in these cells were observed upon 
irradiation, which were consistent with the different absorption 
properties of their cis and trans isomers (Figure 3b and S8-
S10).  In  particular,  maximal  inward  currents  arising  from  
 
Figure 3. (a) Absorption spectra of both isomers of Glu_brAzo1 
and Glu_brAzo2 in PBS:DMSO 1:1, as well as of the PSS mix-
tures obtained under cis-trans (exc = 405 nm) and trans-cis (exc = 
532 nm) photoisomerization. (b) Activation and deactivation 
spectra of GluK2 in HEK293 cells after perfusion of Glu_brAzo1 
or Glu_brAzo2 and irradiation to induce cis-trans (for activation) 
and trans-cis (for deactivation) photoisomerization. 
 
 
Figure 4. Whole-cell current clamp recordings of rat hippocampal 
neurons in culture after perfusion of Glu_brAzo2 (30 μM) and 
irradiation at exc = 390 (purple) and 530 nm (green). Successful 
neuron activation was observed with 390 nm light pulses of (a) 5 
s, (b) 1s, and (c) 0.5 s (1 Hz stimulation), while it was inhibited 
upon perfusion of DNQX (10 μM). Neurons were current 
clamped at -60 mV and, to truly report on their GluK2-mediated 
gating and connectivity, no Concanavalin A was used to prevent 
receptor desensitization after activation. 
receptor activation were measured at exc = 390-400 nm (i.e. 
when inducing cis-trans photoisomerization of the PCLs). 
Minimal signals due to receptor deactivation were instead 
detected in the dark (i.e. for cis-Glu_brAzo1-2) and at exc > 
450 nm (i.e. upon trans-cis photoisomerization). As predicted 
by our molecular docking calculations, preferential interaction 
between the glutamate agonist ligand and GluK1/GluK2 was 
therefore observed for the trans state of Glu_brAzo1-2, which 
allowed light-induced manipulation of these receptors. 
The trans-active behavior of Glu_brAzo1-2 was further 
demonstrated when measuring their dose-response curves with 
GluK1 and GluK2 in the dark and at exc = 390 (10-300 μM, 
Figure S11). In all the cases, larger inward current signals 
were retrieved for the PSScis-trans mixture generated upon irra-
diation of the initial cis isomer, though with (a) low-to-
moderate photoinduced modulation (ca. 10-35% current in-
crease with respect to the dark) and (b) maximal values that 
were only about 20-40% of those evoked by free glutamate at 
300 μM. Three main factors should account for these results: 
incomplete photoconversion into the active trans isomer, as 
observed in solution (< 60%, Table S1); limited modification 
of the glutamate-binding site affinity upon cis-trans isomeriza-
tion; and the steric effects imparted by the appended diazocine 
group with respect to free glutamate even in its less-hindered 
trans configuration, which are of especial importance for 
GluK2 interaction owing to its narrower ligand binding cavi-
ty.25 Actually, the latter accounts for the lower inward current 
signals with higher light-induced selectivity obtained for this 
receptor. However, it did not prevent Glu_brAzo2 bearing a 
bulkier terminal group to (a) show higher activity (ca. 2-fold 
increase with respect to Glu_brAzo1 for GluK2), as anticipat-
ed by our molecular docking simulations, which (b) is further 
modulated upon photoisomerization, as pursued in our initial 
design. 
Glu_brAzo1-2 were finally tested as photoswitchable neu-
rotransmitters in hippocampal neurons where GluK2 is highly 
expressed.36 Because of their trans-active, cis-stable behavior, 
physiological behavior was not altered upon perfusion of 
Glu_brAzo1-2 in the dark, a clear advantage over most PCLs 
reported for GluRs to date such as GluAzo.5-11 Neuronal firing 
was instead selectively induced upon cis-trans photoisomeri-
zation of Glu_brAzo2 at relatively low concentrations (30 
μM, Figure 4a-c) and weak light intensities (22.0 and 47.4 μW 
mm−2 at exc = 390 and 530 nm, respectively). As a result, 
sequential and sustained trains of action potentials could be 
triggered with Glu_brAzo2 by consecutively switching be-
tween violet and green light illumination, even at low irradia-
tion powers and high excitation frequencies (up to 1 Hz, Fig-
ure 4c). Interestingly, this photoinduced behavior was inhibit-
ed by addition of DNQX,37 a well-known antagonist of kainate 
and AMPA GluRs (Figure 4d), which further demonstrates 
that the efficient photoactivation of hippocampal neurons 
accomplished with Glu_brAzo2 arose from its light-
dependent interaction with GluK2. Noticeably, this clean 
physiological effect was achieved despite the limited activity 
modulation measured upon Glu_brAzo2 photoisomerization 
in GluK2-expressing HEK293 cells (ca. 20% at 30 M con-
centration), while it could not be reproduced with the slightly 
less efficient Glu_brAzo1 agonist (Figure S12). We ascribe 
this situation to the well-known nonlinear behavior of neu-
ronal signaling, since ligand interaction with a minimum frac-
tion of glutamate receptors is needed to overcome the depolar-
ization threshold required to initiate an action potential.5 In 
our case, such threshold was only surpassed with trans-
Glu_brAzo2, probably due to its larger affinity for GluK2, as 
suggested by our measurements in cultured cells. 
In conclusion, we demonstrated in this work the potential of 
C2-bridged azobenzenes for the preparation of azo-based 
photochromic ligands capable of light-controlling neural re-
ceptors, which preserve the larger activity typically observed 
for their trans state while ensuring larger stability for the inert 
cis isomer. By introducing a novel synthetic methodology for 
the preparation of 3,3’-disubstituted diazocines based on an 
Oxone®-mediated intramolecular azocyclization reaction, the 
desired ligands could be obtained with higher yields and larger 
versatility, thus enabling fine-tuning of their light-dependent 
biological response. As a proof of concept, this strategy was 
applied to the preparation of new photoswitchable neuro-
transmitters for the light-induced operation of kainate gluta-
mate receptors, with which we achieved selective neural firing 
upon irradiation without background activity in the dark. 
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